Precision immunotherapy for next-generation medicine.
Cellaris Biotech is a Portuguese biotechnology company pioneering in vivo immune cell engineering to transform CAR-T therapy. By enabling direct reprogramming of immune cells inside the patient, we eliminate complex ex vivo processes while improving scalability and patient access.
Our proprietary Dual Viral Platform Architecture combines targeted integrative and non-integrative systems, to ensure precise control of CAR expression, safety, and durability through advanced vector and construct engineering.
High-precision delivery systems with tunable integration profiles.
Reprogramming of immune cells within the patient.
Enhanced signaling domains and safety-engineered configurations.
Integrative and non-integrative systems tailored to therapeutic needs.
Engineering immune cells directly in the patient could simplify logistics, shorten vein-to-vein time, improve scalability and access, and enable repeat dosing or rapid iteration as disease evolves.
Technology: Smart viral vectors utilizing controlled integration for high cellular precision
In Vivo Advantage: Direct transformation of T cells, NK cells, and macrophages into therapeutic effectors inside the patient body
Tagline: No Ex-Vivo manipulation
CAR-T through
In Vivo Engineering
Multi-step, centralized manufacturing increases turnaround time and overall treatment costs.
Manufacturing capacity, logistics, and site availability limit the number of patients who can be treated and the speed at which treatment can be delivered.
By combining scientific rigor with translational vision, Cellaris Biotech is developing scalable, next-generation immune engineering platforms.
Event · Conference
João Gonçalves PhD, presented research on lentiviral platforms for transient and integrative in vivo targeting.
Read more
Platform · Safety
Our LVNI vector demonstrates a complete absence of genomic integration, thereby minimizing mutagenic risk.
Read more